LAVA Therapeutics N.V.(LVTX)Earnings, Financials & Key Ratios
LVTX•NASDAQ
$1.74
Price updated Jun 20, 2026
AboutLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Show more
- Revenue$12M+77.0%
- EBITDA-$29M+31.7%
- Net Income-$25M+40.0%
- EPS (Diluted)-0.94+40.1%
- Gross Margin100%+105.9%
- EBITDA Margin-243.92%+61.4%
- Operating Margin-247.81%+61.3%
- Net Margin-209.6%+66.1%
- ROE-63.64%-4.3%
LVTX Price & Volume
LAVA Therapeutics N.V. (LVTX) stock price & volume — 10-year historical chart
Loading chart...
LVTX Growth Metrics
LAVA Therapeutics N.V. (LVTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years30.84%
TTM-32.06%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM15.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.55%
Return on Capital
10 Years-74.01%
5 Years-62.82%
3 Years-36.43%
Last Year-39.7%
Peers Comparison
Key metrics vs top competitors for LAVA Therapeutics N.V. (LVTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.74 | $45.77M | -1.85 | 77.01% | -209.6% | -63.64% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $55.83 | $8.55B | 20.16 | 87.32% | 65.95% | 87.36% | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $4.81 | $305.74M | -4.08 | 0.78% | -44.79% | -147.8% | — | |
| $15.05 | $1.1B | -12.14 | 13.65% | -185.71% | -28.77% | — |
Compare LVTX vs Peers
LAVA Therapeutics N.V. (LVTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when LVTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LVTX Frequently Asked Questions
LAVA Therapeutics N.V. (LVTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is LAVA Therapeutics N.V.'s revenue?
LAVA Therapeutics N.V. (LVTX) reported $5.0M in revenue for fiscal year 2024.
How fast is LAVA Therapeutics N.V. growing?
LAVA Therapeutics N.V. (LVTX) grew revenue by 77.0% over the past year. This is strong growth.
Is LVTX profitable?
LAVA Therapeutics N.V. (LVTX) reported a net loss of $23.3M for fiscal year 2024.
Dividend & Returns
What is LVTX's return on equity?
LAVA Therapeutics N.V. (LVTX) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.
What is LAVA Therapeutics N.V.'s free cash flow?
LAVA Therapeutics N.V. (LVTX) had negative free cash flow of $31.7M in fiscal year 2024, likely due to heavy capital investments.